MONOCLONAL T LYMPHOCYTE FACTOR REGULATION OF MYELOMA

MOPC-315是分泌抗TNP IgA的BALB/c浆细胞瘤 由淋巴细胞样非分泌细胞组成，伊加315- 分泌浆细胞样细胞和中间细胞。 过程中的 体内生长的淋巴样、非分泌型315细胞增殖 并分化为分泌伊加315的浆细胞样细胞。 这种生长和分化可以在体内和体内调节， 通过载体特异性辅助、抑制和反抑制进行体外研究 T细胞。 一些特异性调节T细胞分化的 不仅识别载体抗原，而且识别伊加315独特位。 的 本文所述的实验涉及生产和 绵羊单克隆T细胞系的鉴定 红细胞（SRBC）免疫BALB/c小鼠， 抑制或反抑制生长或分泌 MOPC-315细胞的体外分化。 因为在体内和体内 体外实验表明，调节是由于T 细胞释放的可溶性调节因子，这种授予也是 专注于纯化、生化和血清学 对调控因素的描述。 这是特别 重要的是，因为所有的调节细胞似乎都作用于 MOPC-315的非分泌性淋巴细胞样群体， 通过表面伊加315独特位与细胞相互作用 或通过表面伊加315结合TNP-SRBC。 因此，信息 关于这些因素的结构-功能关系是可能的 获取。 独特型315特异性分化辅助性T细胞（THd） 细胞、SRBC特异性分化抑制T（Tsd）细胞，和 独特型315特异性分化抑制因子T 细胞单克隆系已经产生。 多克隆THd 细胞可以保护小鼠免受MOPC-315肿瘤生长， 通过诱导细胞增殖， 它的区别。 实验旨在确定 THd细胞可以抑制肿瘤进展的机制 小鼠和使用纯化的独特型315-和SRBC- 作为抗MOPC治疗药物的特异性THd辅助因子- 315细胞的体内试验。 这些实验可能 表明调节刺激以及细胞毒性 干预可以对某些肿瘤产生治疗效果。 进展

MOPC-315 is an anti-TNP IgA-secreting BALB/c plasmacytoma which is composed of lymphocytoid, non-secretory cells, IgA 315- secreting plasmacytoid cells, and intermediate cells. During in vivo growth the lymphocytoid, non-secretory 315 cells proliferate and differentiate into the IgA 315-secreting plasmacytoid cells. That growth and differentiation can be regulated in vivo and in vitro by carrier-specific helper, suppressor, and contrasuppressor T cells. Some of the differentiation regulating T cells specifically recognize not only carrier antigen but also IgA 315 idiotopes. The experiments described herein involve production and characterization of monoclonal T cell lines from sheep erythrocyte (SRBC)-immune BALB/c mice which can enhance, suppress, or contrasuppress the growth or secretory differentiation of MOPC-315 cells in vitro. Since in vivo and in vitro experiments suggest that regulation is occurring due to T cell release of soluble regulatory factors, this grant also is focused on purification, and biochemical and serological characterization of the regulatory factors. This is particularly important since all of the regulatory cells appear to act on the non-secretory lymphocytoid population of MOPC-315 and appear to interact with the cells through either surface IgA 315 idiotopes or through surface IgA 315 binding TNP-SRBC. Thus, information about structure-function relationships of these factors is possible to obtain. Idiotype 315-specific differentiation helper T (THd) cell, SRBC-specific differentiation suppressor T (Tsd) cell, and idiotype 315-specific differentiation contrasuppressor T (TCSd) cell monoclonal lines have already been produced. Polyclonal THd cells can protect mice against MOPC-315 tumor growth by apparently reducing the cells proliferative potential by inducing its differentiation. Experiments designed to determine the mechanism by which THd cells can inhibit tumor progression in mice and efficacy of using purified idiotype 315- and SRBC- specific THd helper factors as therapeutic drugs against MOPC- 315 cells in vivo are described herein. These experiments may demonstrate that regulatory stimuli as well as cytotoxic intervention can have therapeutic effects on some tumors' progression.